CAR-T Operations: Making Personalized Medicine a Reality

By John Duffin, CEO, Pinnaql

This is a reprint of the original article featured by BioProcess International in their Featured Report: Manufacturing Cell and Gene Therapies, originally published in April, 2026.

Over the past several decades, the life sciences industry has made extraordinary progress as science, engineering, and technology intersect to improve human health. Few innovations epitomize that progress more powerfully than chimeric antigen receptor (CAR) T-cell therapy. It is not simply a milestone in oncology; it represents a fundamental shift in how the healthcare industry can define, manufacture, and deliver personalized medicine.

Nearly 25 years ago, I lost a close friend and fellow Purdue University Boilermaker to cancer. At the time, he was receiving exploratory CAR-T therapies that were still in their infancy. The science was promising, but the manufacturing infrastructure, process controls, and data systems were nowhere near what they are today. I often reflect on how different his journey might have been if the operational maturity now found across the advanced therapies sector had existed then. That perspective grounds my belief that CAR-T therapy cannot be just a discovery; it requires building systems that will be capable of reliably delivering hope.

CAR-T technology has made individualized treatment possible. For patients who have exhausted all traditional options, it can offer a second chance. And it underscores an important reality in the biopharmaceutical industry: breakthrough science alone is not enough. Innovation must extend through development, manufacturing, validation, quality systems, and final delivery to patients. Without disciplined execution, even the most promising therapies will struggle to reach those who need them.

Facility Requirements

In conventional pharmaceutical manufacturing, standardized formulations are produced in large volumes for broad patient populations. By contrast, autologous/ex vivo CAR-T therapy operates at a one-patient, one-batch scale. Each treatment begins with collection of a patient’s own T cells by apheresis. Those cells are genetically engineered to recognize and attack cancer cells, then expanded in controlled environments and subjected to rigorous testing, released by quality oversight, and returned to the patient for infusion.

Such an individualized model challenges assumptions embedded in traditional facility design. Conventional biomanufacturing plants are optimized for linear flow and predictable batch schedules. CAR-T facilities must accommodate dynamic workflows in which each lot moves on its own timeline.

Strategic Operations

Chain of identity and chain of custody are central pillars of CAR-T operations. In an autologous therapy model, there is no backup lot. A labeling error or data mismatch cannot be corrected by pulling from inventory. Such problems directly jeopardize patient safety.

To mitigate that risk, mature programs embed identity controls from the outset. Barcodes, RFID-enabled labeling systems, and scanning checkpoints track material from collection through infusion. Electronic systems validate patient identifiers before a process step can proceed.

Execution becomes the differentiator between organizations that scale successfully and those that struggle. Successful CAR-T programs often establish commercial-grade quality systems while in late-stage clinical trials. Their sponsors design standard operating procedures that accommodate variability without constant revision.

Information Technologies

Regulatory agencies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have demonstrated both flexibility and rigor in evaluating advanced therapies. Those authorities recognize the innovative nature of CAR-T technology but remain firm in their expectations regarding patient safety, data integrity, and process control.

Data integrity takes on heightened importance in CAR-T manufacturing because every record is patient-specific. A single test result directly determines whether a patient’s treatment will proceed. Ensuring that such records are attributable, legible, contemporaneous, original, and accurate (ALCOA) is fundamental.

Guidance and Collaboration

As CAR-T programs expand across multiple sites and incorporate external partners such as contract development and manufacturing organizations (CDMOs), tight governance becomes even more critical. Enterprise-wide standards for system validation, backup and recovery procedures, data retention, and periodic review create consistency.

Despite the sophistication of the technology involved, CAR-T manufacturing remains deeply human. Operators must execute precise aseptic manipulations. Engineers must troubleshoot equipment under tight timelines. Quality professionals must make release decisions with full awareness of potential patient impacts.

Experience cannot be overstated in this environment. Professionals who have navigated complex validation efforts, regulatory inspections, and accelerated product launches bring perspective that no checklist can replace.

Effective partnerships strengthen those capabilities. Organizations that engage external experts not merely for discrete deliverables but as collaborative extensions of their teams often build stronger internal foundations.

A New Era

CAR-T therapy currently offers a powerful glimpse into the future of medicine. It is personal, data-driven, and continuously advancing. To realize its promise fully, companies must invest not only in discovery, but also in the operational excellence that transforms innovation into deliverable care.

For those of us who have witnessed cancer’s impact firsthand, the work of CAR-T development carries profound meaning. The details matter because lives depend on them. When we align scientific vision with disciplined execution, and when we elevate compliance and empower innovation together, we move closer to a future in which personalized medicine will fulfill its potential as a reliable standard of care.